All In Biotech

Drug Trial Radar · NCT05978284

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

A Phase 1/2 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Oct 27, 2023

Primary completion

Sep 2026

Study completion Oct 2026

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.

Conditions

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma

Interventions

  • ZG006Biological

    ZG006 will be administered as an intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of dose-limiting toxicity (DLT)Time frame: Up to 28 days
  2. Maximum Tolerated Dose (MTD) of ZG006Time frame: Up to approximately 1 year
  3. Determine the Recommended Phase 2 Dose (RP2D)Time frame: Up to approximately 1 year
  4. Number of participants with adverse events (AEs)Time frame: Up to approximately 2 year
  5. Number of participants with serious adverse events (SAEs)Time frame: Up to approximately 2 year
  6. Incidence of abnormal laboratory resultsTime frame: Up to approximately 2 year
  7. Changes of ECGs from baselinesTime frame: Up to approximately 2 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.